2,4-Dichloropyridine → 4-chloro-N-(2-methylpyrazol-3-yl)pyridin-2-amine

HRID 152

반응식

HRID 152 반응식
Clc1ccnc(Cl)c1.Cn1nccc1N>C1COCCO1.CC(C)(C)[O-].CC1(C)c2cccc(P(c3ccccc3)c3ccccc3)c2Oc2c(P(c3ccccc3)c3ccccc3)cccc21.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.O=C(/C=C/c1ccccc1)/C=C/c1ccccc1.[Na+].[Pd].[Pd]>Cn1nccc1Nc1cc(Cl)ccn1

참가 물질

7

반응 조건

온도
130 °C

실험 절차

TRIS(DIBENZYLIDENEACETONE)DIPALLADIUM(0) (251 mg, 0.27 mmol) was added in one portion to 2,4-dichloropyridine (1000mg, 6.76 mmol), 1,3-dimethyl-1H-pyrazol-5-amine (826 mg, 7.43 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (461 mg, 0.80 mmol) and sodium tert-butoxide (974 mg, 10.14 mmol) in 1,4-dioxane (60 mL) warmed to 130ºC over a period of 10 minutes under nitrogen. The resulting mixture was stirred at 130°C for 20 hours. The reaction mixture was evaporated to dryness and redissolved in DCM (150 mL). Solids were filtered off by suction and the filtrate subsequently washed with water (100 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 4% MeOH in DCM. Pure fractions were evaporated to dryness to afford 4-chloro-N-(1-methyl-1H-pyrazol-5-yl)pyridin-2-amine (802 mg, 56.9 %) as a yellow oil which crystallised on standing.

출처 및 근거

ORD 기록
ord-3c8e64b916074a0fa79f8b674402d3e9
출처 데이터셋
750 AstraZeneca ELN dataset
원본 링크
출처 보기

연결된 노트

불러오는 중…